Overview

* Aveanna Q3 revenue grows 22.2% yr/yr, beating analyst expectations

* Company reports Q3 net income of $14.1 mln, reversing prior year loss

* Aveanna raises full-year 2025 revenue guidance to over $2.375 bln

Outlook

* Aveanna raises full-year 2025 revenue guidance to over $2.375 bln from over $2.3 bln

* Company increases full-year 2025 adjusted EBITDA guidance to over $300 mln from over $270 mln

Result Drivers

* PDS SEGMENT GROWTH - Revenue increase primarily driven by $104.9 mln growth in PDS segment

* STRATEGIC TRANSFORMATION - CEO Jeff Shaner attributes revenue and EBITDA growth to strategic transformation efforts

* OPERATIONAL EXCELLENCE - CFO Matt Buckhalter highlights operational excellence and disciplined execution as drivers of improved results

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $621.90 $592.22

Revenue mln mln (9

Analysts

)

Q3 EPS $0.06

Q3 Net $14.10

Income mln

Q3 $80.10

Adjusted mln

EBITDA

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Aveanna Healthcare Holdings Inc ( AVAH ) is $9.25, about 0.4% above its November 5 closing price of $9.21

* The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)